(Reuters) - Aurobindo Pharma Ltd reported a 12 percent fall in quarterly profit on Thursday and missed analysts' expectations, hurt by higher expenses.
Net profit was 4.56 billion rupees ($66.40 million) in the first quarter ended June 30, compared with 5.19 billion rupees a year earlier, the Hyderabad-headquartered company said in a statement.
Analysts on average had expected a net profit of 5.29 billion rupees, according to estimates by Thomson Reuters I/B/E/S.
Expenses rose 24.4 percent to 37.23 billion rupees, while revenue from operations stood at 41.82 billion rupees.
($1 = 68.6750 Indian rupees)
Also Read
(Reporting by Sharnya G and Chris Thomas in Bengaluru; Editing by Subhranshu Sahu)
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app